Results 31 to 40 of about 89,590 (297)
PLoS ONE, 2014 About 8% of the adult population is taking angiotensin-converting enzyme (ACE) inhibitors to treat cardiovascular disease including hypertension, myocardial infarction and heart failure. These drugs decrease mortality by up to one-fifth in these patients.
Miklós Fagyas +13 more
doaj +1 more source
Kidney Research and Clinical Practice, 2013 Background: Angiotensin converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) may induce acute kidney injury (AKI). The aim of this study was to evaluate the role of the resistive index (RI), which reflects renal artery resistance on ...
Eun Seok Kim +9 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background PIK3CA‐related overgrowth spectrum (PROS) includes several rare overgrowth disorders resulting from somatic gain‐of‐function mutations in PIK3CA. Despite treatment advances, including the recent approval of alpelisib for PROS in the United States, literature detailing the patient experience with PROS is limited.
Vamsi Bollu +8 more
wiley +1 more source
Folia Medica Indonesiana, 2017 Heart failure (HF) is the final common stage of many diseases of the heart. NT-proBNP levels are increased in HF and correlate well with ventricular wall stress and severity of HF. Combination therapy with Bisoprolol and ACE-inhibitor decreases NT-proBNP
Reine Risa Risthanti +2 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background An internal tandem duplication in the gene encoding Fms‐like tyrosine kinase 3 (FLT3‐ITD) is associated with high relapse risk and poor prognosis in acute myeloid leukemia (AML) and plays a crucial role in treatment decisions. Measurable residual disease (MRD) analysis of FLT3‐ITD during and after treatment has shown prognostic ...
Sofie Johansson Alm +11 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta +6 more
wiley +1 more source
Impact of angiotensin converting enzyme inhibition on post- coronary artery bypass interleukin 6 release [PDF]
, 2002 Background: Angiotensin 1 converting enzyme (ACE) inhibitors reduce morbidity and mortality after coronary artery bypass graft surgery (CABG). This benefit may result from an anti- inflammatory action.
Humphries, S.E. +5 more
core
Use of ACE-inhibitors and quality of life in an older population
, 2018 Background: Improved ability to treat chronic diseases have increased the interest in measuring health-related quality of life (HRQoL) in older adults. Hypertension and heart failure have been associated with decreased HRQoL.
Bernabei, Roberto +2 more
core +1 more source
Cardiovascular risk, metabolic disturbances, and the choice of antihypertensive therapy
Кардиоваскулярная терапия и профилактика, 2011 Aim. To study antihypertensive and metabolic effects of combined antihypertensive therapy with fixed doses of ACE inhibitor and thiazide-like diuretic (Noliprel®), in comparison with ACE inhibitor monotherapy (ramipril). Material and methods.
M. N. Mamedov +4 more
doaj +1 more source
Conformational changes of blood ACE in chronic uremia. [PDF]
PLoS ONE, 2012 BACKGROUND: The pattern of binding of monoclonal antibodies (mAbs) to 16 epitopes on human angiotensin I-converting enzyme (ACE) comprise a conformational ACE fingerprint and is a sensitive marker of subtle protein conformational changes.
Maxim N Petrov +6 more
doaj +1 more source